LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect.
In a statement, the company, which is developing immunotherapies to treat cancer, said 53-year old Adams had worked as a consultant since 2008, providing the company with guidance through the drug development process.
"Sally has brought to Scancell her expertise in most aspects of drug discovery, including preparation and execution of clinical development plans from research to the clinic, scientific writing, implementation of quality control and documentation systems plus management of the SCIB1 clinical trial itself," the company said in a statement.
"She has worked on a number projects in recent years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction," it added.
Adams will continue to play a role in the development of the company's ImmunoBody and Moditope platforms, it added.
Scancell shares were up 9.1% at 32.72 pence Thursday morning.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)